| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
University of Southern California Comprehensive Cancer Center, Cancer Research Laboratory, Los Angeles, California 90033
The effects of N-methyl- and N-ethyl-N'-nitro-N-nitrosoguanidines and methyl and ethyl methanesulfonates on DNA synthesis in C3H/10T
mouse embryo fibroblasts and Chinese hamster V79 cells have been analyzed by measuring the incorporation of tritiated thymidine into the trichloroacetic acidinsoluble fraction and the purified DNA of the cells, and by measuring the fraction of parental DNA replicated by equilibrium density sedimentation in neutral cesium chloride gradients. The inhibition of DNA synthesis produced by the alkylating agents at
90% lethal dose was uniformly associated with the cytotoxicity of all four of the agents in both lines of cells. The molar concentrations of the compounds required to inhibit DNA synthesis or produce cytotoxicity also correlated well in a log-log plot, with their potencies in producing DNA lesions that are associated with mutagenesis. However, equitoxic doses of the alkylating agents that inhibited DNA synthesis to equal extents produced frequencies of mutations and of alkali-labile DNA lesions that differed by about an order of magnitude, which did not produce major departures from the linear correlation apparent in the above log-log plot. Therefore, the kinds of DNA lesions that inhibit DNA synthesis and are associated with cytotoxicity in cells treated with the above alkylating agents are not uniformly associated with alkali-labile DNA lesions and gene mutations. Thus, evaluations of mutagenic potency, by assays of DNA synthesis and cytotoxicity, will be falsely high for compounds that predominantly produce DNA lesions that inhibit DNA synthesis and are associated with cytotoxicity. Such evaluations will be falsely low for compounds that predominantly produce DNA lesions that are mutagenic.
1 Supported by Grant CA-21036 from the National Cancer Institute.
2 To whom requests for reprints should be addressed.
Received 7/17/79. Accepted 11/26/79.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |